Treace Medical Concepts, Inc.
TMCI
$7.62
-$0.21-2.68%
| Weiss Ratings | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.43 | |||
| Price History | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.19% | |||
| 30-Day Total Return | -18.68% | |||
| 60-Day Total Return | -0.39% | |||
| 90-Day Total Return | -4.03% | |||
| Year to Date Total Return | -3.18% | |||
| 1-Year Total Return | -35.80% | |||
| 2-Year Total Return | -70.08% | |||
| 3-Year Total Return | -60.50% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -38.54% | |||
| 52-Week Low % Change | 99.74% | |||
| Price | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.74 | |||
| 52-Week Low Price | $3.92 | |||
| 52-Week Low Price (Date) | May 08, 2024 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 490.12M | |||
| Enterprise Value | 484.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.90 | |||
| Earnings Per Share Growth | 10.52% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.33 | |||
| Price/Book (Q) | 4.33 | |||
| Enterprise Value/Revenue (TTM) | 2.31 | |||
| Price | $7.62 | |||
| Enterprise Value/EBITDA (TTM) | -10.05 | |||
| Enterprise Value/EBIT | -8.71 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 62.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 904 373 5940 | |||
| Address | 100 Palmetto Park Place Ponte Vedra, FL 32081 | |||
| Website | www.treace.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -26.54% | |||
| Profit Margin | -26.62% | |||
| Management Effectiveness | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.81% | |||
| Return on Equity | -- | |||
| Income Statement | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 209.36M | |||
| Total Revenue (TTM) | 209.36M | |||
| Revenue Per Share | $3.36 | |||
| Gross Profit (TTM) | 168.26M | |||
| EBITDA (TTM) | -48.16M | |||
| EBIT (TTM) | -55.58M | |||
| Net Income (TTM) | -55.74M | |||
| Net Income Avl. to Common (TTM) | -55.74M | |||
| Total Revenue Growth (Q YOY) | 10.44% | |||
| Earnings Growth (Q YOY) | 92.02% | |||
| EPS Diluted (TTM) | -0.90 | |||
| EPS Diluted Growth (Q YOY) | 89.59% | |||
| Balance Sheet | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 75.68M | |||
| Cash Per Share (Q) | $1.21 | |||
| Total Current Assets (Q) | 161.40M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 112.89M | |||
| Current Ratio (Q) | 4.621 | |||
| Book Value Per Share (Q) | $1.81 | |||
| Total Assets (Q) | 217.09M | |||
| Total Current Liabilities (Q) | 34.93M | |||
| Total Debt (Q) | 69.65M | |||
| Total Liabilities (Q) | 104.20M | |||
| Total Common Equity (Q) | 112.89M | |||
| Cash Flow | TMCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 35.38M | |||
| Cash from Financing (TTM) | 160.00K | |||
| Net Change in Cash (TTM) | -1.63M | |||
| Levered Free Cash Flow (TTM) | -29.98M | |||
| Cash from Operations (TTM) | -37.17M | |||
